Sarepta Therapeutics, Inc. $SRPT Shares Bought by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP lifted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 14,895.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,180 shares of the biotechnology company’s stock after buying an additional 72,692 shares during the quarter. Fulcrum Asset Management LLP owned about 0.07% of Sarepta Therapeutics worth $1,364,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Pictet Asset Management Holding SA grew its holdings in Sarepta Therapeutics by 4,355.1% during the 3rd quarter. Pictet Asset Management Holding SA now owns 689,732 shares of the biotechnology company’s stock worth $12,567,000 after acquiring an additional 674,250 shares during the period. Privium Fund Management B.V. boosted its position in shares of Sarepta Therapeutics by 22.1% in the 3rd quarter. Privium Fund Management B.V. now owns 166,605 shares of the biotechnology company’s stock worth $3,036,000 after purchasing an additional 30,105 shares during the last quarter. Alps Advisors Inc. grew its stake in shares of Sarepta Therapeutics by 31.3% during the third quarter. Alps Advisors Inc. now owns 139,944 shares of the biotechnology company’s stock worth $2,550,000 after purchasing an additional 33,395 shares during the period. CenterBook Partners LP grew its stake in shares of Sarepta Therapeutics by 232.3% during the third quarter. CenterBook Partners LP now owns 153,853 shares of the biotechnology company’s stock worth $2,803,000 after purchasing an additional 107,560 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sarepta Therapeutics during the third quarter worth $98,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $16.68 on Thursday. The business’s 50-day moving average price is $18.87 and its two-hundred day moving average price is $18.57. The company has a current ratio of 3.46, a quick ratio of 2.13 and a debt-to-equity ratio of 0.46. The firm has a market cap of $1.79 billion, a PE ratio of -12.18, a P/E/G ratio of 0.39 and a beta of 0.45. Sarepta Therapeutics, Inc. has a 1-year low of $14.68 and a 1-year high of $24.68.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. Sarepta Therapeutics had a negative return on equity of 0.20% and a negative net margin of 5.86%. The company had revenue of $381.35 million for the quarter, compared to analyst estimates of $352.20 million. During the same quarter last year, the firm posted ($0.13) earnings per share. Sarepta Therapeutics’s revenue was down 4.5% compared to the same quarter last year. As a group, research analysts forecast that Sarepta Therapeutics, Inc. will post 3.27 earnings per share for the current year.

Analyst Ratings Changes

SRPT has been the topic of a number of recent analyst reports. Robert W. Baird set a $18.00 target price on Sarepta Therapeutics in a report on Friday, November 6th. Zacks Research cut Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. HC Wainwright reiterated a “sell” rating and issued a $5.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 5th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 28th. Finally, Deutsche Bank raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating and lifted their price objective for the stock from $14.00 to $18.00 in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $23.67.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.